Life Sciences Blog

Better diabetes treatment can save Medicaid over $4 billion per year




Diabetes is one of the most prevalent and expensive medical conditions in the US, especially among people with low socio-economic status. As the primary health insurer for low-income people in the US, Medicaid is estimated to cover more than 15% of all diabetes patients on their treatment costs.

An analysis of National Health and Nutrition Examination Survey (NHANES, 2007~2012) showed about 13% of Medicaid adult beneficiaries have diabetes. Most them also have other comorbidities such as: hypertension, coronary artery disease, stroke, and heart attack. Better management of diabetes can improve patient health outcomes and reduce medical costs, especially among those with blood glucose level not well controlled.

By simulating the impact of well controlled biometrics on Medicaid enrollee samples from 50 US states with our Disease Prevention Microsimulation Model, we estimated each treated diabetes patient could save $845 ($308 ~ $1490 varied by states) per year in medical expenses as the result of significantly reduced onset of complications over 10 years. Among the subset of patients with uncontrolled glucose level, average per capita saving is almost $1,000 ($361 ~ $1,698 varied by states). 

How six states stack up on savings

         

Overall, we projected better diabetes treatment can potentially reduce Medicaid health care spending by over $4 billion per year. Download the state-by-state results to see the full scope of possible savings.  In addition, you can read our whitepaper on the clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes.

Frank Chen is a Principal Consultant with the Life Sciences practice at IHS Markit.
Posted 9 November 2017

About The Author

Frank Chen is a Consulting Principal in the Life Sciences team at IHS Markit. He has over 10 years of experience in health related outcome research and quantitative analysis including microsimulation, cost effectiveness analysis, statistical modeling and data mining. He specializes in modeling onset and consequences of various chronic conditions among different target cohorts, and forecasting clinical and economic impact as result of intervention and other measures. He also takes the lead in developing and expanding capability of the proprietary Disease Prevention Microsimulation Model, which is a Markov based simulation model that makes annual projection on disease incidents, mortality, health expenditure and indirect economic outcomes through 100+ prediction equations.

Examples of his past and ongoing work include: (1) projection of national and state level clinical and economic burden of chronic diseases; (2) return on investment analysis of a digital intensive behavior counseling program on people at risk for diabetes and cardiovascular disease; (3) budgetary impact of expanding Medicare coverage on obesity treatment; (4) estimation on benefit of improved diabetes treatment to Medicaid beneficiaries; (5) modeling the impact of anti-opioids abuse treatment in the US.

Frank has published on multiple peer reviewed journals such as the American Journal of Managed Care, Journal of Medical Economics, Preventing Chronic Disease, PLOS One, International Journal of Cardiology, BMC medical Genetics etc.

Frank holds a Ph.D. degree in computational biology and an M.S. degree in Statistics from Rutgers University.